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The increasing burden of pneumonia in adults is an emerging health issue in the era of glob-
al population aging. This study was conducted to elucidate the burden of community-onset
pneumonia (COP) and its etiologic fractions in Japan, the world’s most aged society.
Methods
Amulticenter prospective surveillance for COP was conducted from September 2011 to
January 2013 in Japan. All pneumonia patients aged15 years, including those with com-
munity-acquired pneumonia (CAP) and health care-associated pneumonia (HCAP), were
enrolled at four community hospitals on four major islands. The COP burden was estimated
based on the surveillance data and national statistics.
Results
A total of 1,772 COP episodes out of 932,080 hospital visits were enrolled during the surveil-
lance. The estimated overall incidence rates of adult COP, hospitalization, and in-hospital
death were 16.9 (95% confidence interval, 13.6 to 20.9), 5.3 (4.5 to 6.2), and 0.7 (0.6 to 0.8)
per 1,000 person-years (PY), respectively. The incidence rates sharply increased with age;
the incidence in people aged85 years was 10-fold higher than that in people aged 15-64
years. The estimated annual number of adult COP cases in the entire Japanese population
was 1,880,000, and 69.4% were aged65 years. Aspiration-associated pneumonia
(630,000) was the leading etiologic category, followed by Streptococcus pneumoniae-
associated pneumonia (530,000), Haemophilus influenzae-associated pneumonia
(420,000), and respiratory virus-associated pneumonia (420,000), including influenza-
associated pneumonia (30,000).
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Conclusions
A substantial portion of the COP burden occurs among elderly members of the Japanese
adult population. In addition to the introduction of effective vaccines for S. pneumoniae and
influenza, multidimensional approaches are needed to reduce the pneumonia burden in an
aging society.
Introduction
Globally, pneumonia is a major cause of morbidity and mortality in adults [1, 2]. According to
recent estimates, lower respiratory tract infections, including pneumonia, are the fourth most
common cause of death, and 1.9 million adults aged15 years die from lower respiratory in-
fections every year [3]. Studies have shown that the risks of pneumonia and pneumonia-related
death increase with age and are highest among the elderly [2, 4], indicating that the pneumonia
burden is growing in this era of global population aging [5].
Japan is the most aged society in the world; 25% of the Japanese population was aged65
years in 2013 [6, 7]. Although Japanese people have universal access to high-quality medical
care as a virtue of universal health insurance coverage [8], an increasing number of elderly peo-
ple are suffering from pneumonia; the disease is now ranked as the third cause of death in the
country. Elucidating the true burden and etiologic fractions is crucial for effective disease con-
trol programs; however, the epidemiology of pneumonia remains largely unknown in Japan.
Adult pneumonia has a multi-factorial etiology. Streptococcus pneumoniae is the leading
cause of adult community-acquired pneumonia (CAP) throughout the world [4, 9, 10], but it
has been declining in high-income countries as a result of the wide use of antibiotics and the in-
troduction of pneumococcal vaccines [11]. Meanwhile, non-pneumococcal pneumonia, particu-
larly among elderly people, is gaining attention. Aspiration is considered a major cause of
pneumonia in the elderly [12]. The spread of drug-resistant strains is an emerging problem; the
risk of drug-resistant pneumonia is particularly high in cases of health care-associated pneumo-
nia (HCAP) and hospital-acquired pneumonia (HAP) [13]. In addition to bacterial pathogens,
respiratory viruses (RVs), including influenza and respiratory syncytial virus (RSV), play impor-
tant roles in the development of pneumonia among the elderly [14]. This variety of etiologies
makes controlling pneumonia among the elderly challenging. However, despite improvements
in microbiological diagnostic methods, the etiology of pneumonia has not been fully character-
ized in aged societies.
This prospective multicenter surveillance of adult community-onset pneumonia (COP)
covered four major islands in Japan. The study objectives were to establish the age group- and
etiology-specific incidences of pneumonia at a population level and to estimate the burden of
pneumonia in the entire Japanese adult population.
Methods
Ethics
This study was conducted in accordance with the Guideline for Ethical Aspects in Epidemio-
logical Study (Ministry of Health, Labor and Welfare [MHLW], 2008) and was approved by
the Institutional Review Boards (IRBs) of the Institute of Tropical Medicine, Nagasaki Univer-
sity, Ebetsu City Hospital, Kameda Medical Center, Chikamori Hospital, and Juzenkai Hospi-
tal. Written informed consent was obtained from the majority of the participants or their
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guardians. The requirement for obtaining written consent from all participants was waived by
all IRBs because of the study’s observational nature without any deviation from the current
medical practice. Hospital doctors verbally described the study objectives and methods to eligi-
ble patients and their guardians during their consultations. We also provided the necessary in-
formation to patients and their guardians using a standardized questionnaire sheet and a
poster presentation at the outpatient department. Anonymized data were used for the analysis.
Study setting
According to the national statistics, the total population in Japan was 127 million in 2013 [7].
Of this population, 25.1% were65 years of age, and 3.6% were85 years of age [7]. Although
no national recommendation for the 23-valent polysaccharide pneumococcal vaccine (PPV23)
existed at the time of study, the cost of PPV23 was partially or fully subsidized by the local gov-
ernment. The estimated coverage rate of PPV23 for adults aged65 years was approximately
25% in 2013 [15].
Case enrollment
The study was conducted at four community-based hospitals in four prefectures (Hokkaido,
Chiba, Kochi, and Nagasaki) in Japan from September 2011 through January 2013. One hospi-
tal is located on each of the four main islands (Ebetsu City Hospital in Hokkaido, Kameda
Medical Center in Honshu, Chikamori Hospital in Shikoku, and Juzenkai Hospital in Kyusyu).
Because of Japan’s universal health insurance system, 70% of the medical costs for people aged
<70 years and 80–90% of the medical costs for people aged70 years are covered, regardless
of whether the individual is treated in the private or public sector [8]. Therefore, we assume
that the characteristics of the pneumonia patients visiting these hospitals do not significantly
differ from those visiting neighboring hospitals.
Enrollment criteria
All the outpatients were screened by hospital physicians, and eligible patients were identified
using a standardized case definition. Patients who fulfilled all the following criteria were en-
rolled in the study: 1) age15 years, 2) with symptoms compatible with pneumonia (e.g.,
fever, cough, sputum, pleuritic chest pain, and dyspnea), and 3) with new pulmonary infiltrates
on chest X-ray (CXR) or computed tomography (CT) scan films that were consistent with
pneumonia. To ensure that all eligible cases were enrolled, the study investigators screened the
hospital database for International Classification of Diseases, 10th revision (ICD-10) codes and
reviewed hospital medical records.
All the enrolled cases were classified into CAP and HCAP groups according to the defini-
tions in the ATS/IDSA guideline [16, 17]. If a patient developed the disease 48 hours after ad-
mission, he or she was classified as having HAP and was excluded. Repeated episodes of
pneumonia in the same patient within a 2-week period were regarded as a single episode.
Data collection
Demographic and clinical information were collected from patients and medical charts using a
standardized data collection form. Sputum and blood samples were collected from the partici-
pants on admission; sputum was induced with the inhalation of hypertonic saline solution if
the patients were unable to cough up sputum. CXRs were taken from all patients within 24
hours of admission, and CT scans were ordered by clinicians based on their judgment.
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Microbiological test
Clinical specimens were immediately transported to the laboratory at each hospital. Gram
staining was performed on each sputum specimen, and the specimen quality was evaluated by
trained laboratory technicians according to Miller and Jones’ classification [18]. All sputum
samples were examined using semi-quantitative or quantitative culture methods.
Sputum samples were further tested at the Institute of Tropical Medicine, Nagasaki Univer-
sity, using in-house multiplex polymerase chain reaction (PCR) assays to identify bacterial and
viral pathogens. Three typical bacterial pathogens (S. pneumoniae, H. influenzae, andM. catar-
rhalis), three atypical bacterial pathogens (Mycoplasma pneumoniae, Chlamydophila pneumo-
niae, and Legionella pneumophila), and thirteen viral pathogens (influenza A virus, influenza B
virus, respiratory syncytial virus [RSV], human metapneumovirus [HMPV], human parainflu-
enza virus [HPIV] types 1–4, human rhinovirus [HRV], human coronavirus [HCoV] 229E/
OC43, human adenovirus [HAdV] and human bocavirus) were tested using different sets of
multiplex PCR. Details about the primers and PCR methods used have been described previ-
ously [19, 20]. We also performed urinary antigen tests for S. pneumoniae and L. pneumophila
using commercial kits (Binax NOW Streptococcus pneumoniae, Binax NOW Legionella; Alere
Inc., Waltham, MA, USA). All pneumococcal isolates were serotyped using the capsular
quelling method.
Etiological category
The etiological category of pneumonia was defined according to the microbiological findings of
sputum, blood, and urine samples. The causative pathogens were determined by hospital clini-
cians and study investigators. Because no culture, PCR or rapid urine test is perfect, we estimated
the prevalences of S. pneumoniae and H. influenzae using two different methods: 1) positivity
was defined if either a sputum culture or a urinary antigen test showed a positive result (standard
estimation), and 2) positivity was defined if a sputum culture, sputum PCR, or urinary antigen
test showed a positive result (maximum estimation).
To estimate the etiology-specific incidence of pneumonia, aspiration-associated pneumo-
nia was defined independent of microbiological profiles. Cases were classified as aspiration-
associated pneumonia when the patients had any of the following known risk factors:
episodes of aspiration, the presence of dysphagia, consciousness disturbances, neuromuscular
diseases, cerebrovascular diseases, tube feeding, and bedridden status [21]. The prevalence
of aspiration-associated pneumonia was calculated separately from those of pathogen-
specific category.
The estimation of pneumonia burden
The age-group specific incidence rates of pneumonia, hospitalization and death in the four pre-
fectures were estimated using the surveillance data and the national statistics. We used the
pneumonia-outpatient ratio (POR)-based estimation model that was used in our previous
study [22]. In this model, the number of age group-specific pneumonia cases was estimated
using the age group-specific number of outpatients and the age group-specific POR. PORs
were calculated for hospitals and clinics separately. The model used to estimate the number of




Iij: the annual incidence of pneumonia in age group i and prefecture j
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Cijk: the annual number of outpatients reported to the patient survey in age group i, prefec-
ture j, and facility type k (k = 1, hospitals; k = 2, clinics)
αijk: the ratio of confirmed pneumonia patients to the number of total outpatients in age
group i, prefecture j, and facility type k
Pij: the population in age group i and prefecture j
Cijk was obtained from the patient survey conducted by the MHLW in 2011 [23]. The survey
was conducted at hospitals and clinics on one designated date set for each hospital on one of
three days in October. Pij was obtained from the national demographic survey in 2012 [7].
The proportion of pneumonia cases among outpatients in hospitals (αij1) was calculated
from the surveillance data. To estimate the proportion of pneumonia cases among outpatients
in clinics (αij2), we obtained the clinic databases from two clinics in Nagasaki City. Pneumonia
diagnosis was confirmed using the case definition identical to that used for the hospital-based
surveillance. α was estimated for each age group using curve fitting. Age-standardized rates
were calculated using the WHO world standard population [24]. The number of pneumonia
cases in the entire Japanese population was estimated assuming that the incidence rates (Iij)
were constant across all prefectures.
Results
Case characteristics
During the study period, a total of 932,080 patients visited the study hospitals; 1,935 of these
patients were enrolled in the study. After excluding 163 cases that did not meet the criteria,
1,772 patients were eligible for our analysis (see supplementary material, S1 Fig). CT scans
were administered to 1,332 patients (75.2%), including 110 (8.3%) who did not demonstrate
any infiltrates on their CXRs. The demographic and clinical characteristics of the enrolled
cases are shown in Table 1. Fifty-nine percent of all patients were male, and the median age
was 77 years (range: 15 to 103). Seventy-five percent of the patients were elderly people aged
65 years, and 57% were aged75 years. The case fatality rate was 8%. Seventy-two percent of
our cases were hospitalized, and these cases were more likely to be male, older, smokers, and
classified as having HCAP; more likely to have underlying conditions, aspiration-associated
conditions, and severe conditions; more likely to visit the hospital early; and more likely to
have a fatal outcome compared with outpatients.
Microbiology
Among 1,594 sputum samples tested using conventional cultures, causative bacterial pathogens
were isolated from 759 (48%) samples; 719 (45%) were monoclonal and 40 (3%) were polyclon-
al (Table 2).H. influenzae was the most common bacterial pathogen isolated (10%), followed
by S. pneumoniae (9%).H. influenzae was more frequently isolated from outpatient cases,
while Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli were more frequently
isolated from hospitalized cases. Among the 718 sputum samples tested using multiplex PCR,
359 (50%) were positive for any bacterial pathogens; 20% were positive for S. pneumoniae, and
18% were positive for H. influenzae. H. influenzae andM. pneumoniae were more frequently
detected in samples from outpatient cases than those from hospitalized cases.
S. pneumoniae was isolated by blood culture from 2.9% (n = 7/1,039) of cases, and S. pneu-
moniae urinary antigen was detected in 13% (n = 132/992). Taken together, 26.2% of samples
were positive for S. pneumoniae either by culture, PCR, or urinary antigen tests. Among 142
S. pneumoniae isolates, 100 were serotyped; serotype 3 was the most dominant (n = 22, 22%),
followed by serotypes 11A (n = 10, 10%) and 19F (n = 8, 8%). PPV23 covered 67% of all
Community-Onset Pneumonia in Japan
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serotypes, and 54% were covered by 13-valent pneumococcal conjugate vaccine (PCV13) (see
supplementary material, S2 Fig).
Multiplex PCR was used to test 1,201 sputum samples for RVs, and 23% of the samples
were positive for at least one RV (Table 2). HRV was the leading virus identified, followed by
InfA and RSV. The positivity rates for RVs were similar between the outpatient cases and the
hospitalized cases. Among 717 sputum samples tested for viral and bacterial PCRs, 105 (15%)
were both positive.
Aspiration-associated pneumonia
Among all 1,722 patients, 677 (38.2%) were with aspiration-associated conditions (ie, aspira-
tion-associated pneumonia): 373 (21.1%) had episodes of aspiration, 149 (8.4%) dysphagia, 81
(4.6%) consciousness disturbances, 143 (8.1%) neuromuscular diseases, 373 (21.1%) cerebro-
vascular diseases, 21 (1.2%) tube feeding, and 148 (8.4%) bedridden status. Among 629 sputum
samples available from aspiration-associated pneumonia, Staphylococcus aureus was the most
common bacterial pathogen isolated by culture (10%), followed by S. pneumoniae (7%) and
Klebsiella pneumoniae (7%) (see supplementary material, S1 Table). S. pneumoniae and
H. influenzae were less frequently detected in samples from aspiration-associated pneumonia
than those from non-aspiration-associated pneumonia by culture and PCR.
Table 1. Demographic and clinical characteristics of patients with community-onset pneumonia in Japan.
Total Outpatients Inpatients P-value*
n = 1,772 n = 505 n = 1,267
Male sex 1,040 (59%) 262 (52%) 778 (61%) P<0.001
Age group
15–49 years 202 (11%) 124 (25%) 78 (6%) P<0.001†
50–64 years 242 (14%) 121 (24%) 121 (10%)
65–74 years 316 (18%) 95 (19%) 221 (17%)
75–84 years 562 (32%) 111 (22%) 451 (36%)
85 years and older 450 (25%) 54 (11%) 396 (31%)
HCAP 572 (32%) 47 (9%) 525 (41%) P<0.001
With underlying diseases‡ 1,609 (91%) 389 (77%) 1220 (96%) P<0.001
With aspiration-associated conditions 677 (38.2%) 52 (10%) 625 (49%) P<0.001
Current/ex-smoker, n = 1,345 748 (56%) 170 (50%) 578 (57%) P = 0.023
PPV 23-vaccinated, n = 1,028 356 (35%) 94 (32%) 262 (36%) P = 0.278
Symptoms >7 days§, n = 1,735 255 (15%) 113 (23%) 142 (11%) P<0.001
Pre-hospital antibiotics, n = 1,742 306 (18%) 83 (17%) 223 (18%) P = 0.565
CURB65 >3, n = 1,721 182 (11%) 5 (1%) 177 (14%) P<0.001¶
Deceased 140 (8%) 2 (0%) 138 (11%) P<0.001¶
* Characteristics were compared between outpatients and inpatients using chi-square tests unless otherwise indicated.
† A score test for trend was performed.
‡ Underlying diseases included diabetes mellitus, hypertension, hyperlipidemia, chronic heart disease, cerebrovascular disease, liver disease, renal
disease, collagen vascular disease, chronic lung disease, neuromuscular disease, and malignant disease.
§ The period from onset to hospital visit.
¶ Fisher’s exact test was performed.
doi:10.1371/journal.pone.0122247.t001
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The burden of COP
The overall annual incidence rate of adult pneumonia in the four prefectures was 16.9 per
1,000 PY (95% CI, 13.6 to 20.9 per 1,000 PY) in Japan, and the ASR was 10.2 (7.7 to 13.3;
Table 3). The incidence rate was highest in Kochi (22.8 per 1,000 PY) and lowest in Chiba
Table 2. Microbiological profiles of patients with community-onset pneumonia.
Total Outpatients Inpatients
No. positive (%) No. positive (%) No. positive (%) P value*
Sputum culture performed n = 1,594 n = 417 n = 1,177
Haemophilus influenzae 161 (10) 67 (16) 94 (8) <0.001
Streptococcus pneumoniae 142 (9) 44 (11) 98 (8) 0.17
Staphylococcus aureus 121 (8) 16 (4) 105 (9) 0.002
Moraxella catarrhalis 90 (6) 31 (6) 59 (5) 0.2
Pseudomonas aeruginosa 81 (5) 14 (3) 67 (6) 0.062
Klebsiella pneumoniae 54 (3) 3 (1) 51 (4) <0.001†
Escherichia coli 36 (2) 3 (1) 33 (3) 0.012†
Other bacterial pathogens 113 (6) 7 (1) 106 (8) <0.001
Any bacterial pathogens 759 (48) 176 (42) 583 (50) 0.01
Sputum bacterial PCR performed n = 718 n = 236 n = 482
S. pneumoniae 146 (20) 51 (22) 95 (20) 0.113
H. influenzae 130 (18) 63 (27) 67 (14) <0.001
M. catarrhalis 98 (14) 33 (14) 65 (14) 0.855
M. pneumoniae 38 (5) 24 (10) 14 (3) <0.001
C. pneumoniae 6 (1) 2 (1) 4 (1) 1†
L. pneumophila 0 (0) 0 (0) 0 (0) -
Any bacterial pathogens 359 (50) 147 (63) 212 (44) <0.001
Sputum viral PCR performed n = 1,201 n = 302 n = 899
HRV 114 (9) 32 (11) 82 (9) 0.449
Influenza A 64 (5) 13 (4) 51 (6) 0.36
RSV 51 (4) 9 (3) 42 (5) 0.207
HMPV 21 (2) 9 (3) 12 (1) 0.059
Other RVs‡ 45 (4) 14 (5) 31 (3) 0.347
Any RVs 277 (23) 71 (24) 206 (23) 0.832
Sputum viral and bacterial PCR performed n = 717 n = 236 n = 481
Any RVs + any bacterial pathogens 105 (15) 46 (19) 59 (12) 0.01
Blood culture performed n = 1,039 n = 132 n = 907
E. coli 11 (1.1) 0 (0) 11 (1) 0.377†
S. pneumoniae 7 (1) 0 (0) 7 (1) 1†
K. pneumoniae 6 (1) 0 (0) 6 (1) 1†
S. aureus 4 (0) 0 (0) 4 (0) 1†
H. influenzae 2 (0) 0 (0) 2 (0) 1†
Urinary antigen test for S. pneumoniae performed n = 992 n = 247 n = 745
S. pneumoniae 132 (13) 87 (12) 45 (16) 0.121
HRV = human rhinovirus; RSV = respiratory syncytial virus; HMPV = human metapneumovirus
* Positive rates were compared between outpatients and inpatients using chi-square tests unless otherwise indicated.
† Fisher's exact test was performed.
‡Other RVs included HPIV2 (n = 10), HPIV3 (n = 10), HPIV1 (n = 9), influenza B (n = 6), HCoV (human coronavirus) (n = 4), and HAdV (human
adenovirus) (n = 4).
doi:10.1371/journal.pone.0122247.t002
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0.8 (0.7 to 1) 0.5 (0.4 to 0.6)
CAP = community-acquired pneumonia; CI = confidence interval; HCAP = health care-associated pneumonia; PDR = potentially drug-resistant;
RV = respiratory virus.
*The WHO standardized population was used.
†Positivity was defined when a sputum culture, sputum PCR, or urinary antigen test showed a positive result.
‡Positivity was defined when a sputum culture or urinary antigen test showed a positive result.
§Positivity was defined when a sputum culture or sputum PCR showed a positive result.
¶Positivity was defined when a sputum culture showed a positive result.
#PDR bacterial pathogens, including methicillin-resistant Staphylococcus aureus, extended spectrum beta lactamase-producing gram-negative bacilli,
Pseudomonas aeruginosa, and Stenotrophomonas maltophilia
doi:10.1371/journal.pone.0122247.t003
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(13.7 per 1,000 PY), while the ASR did not differ significantly by prefecture, ranging from 9 to
11.5 per 1,000 PY (see supplementary material, S2 Table). The rate was higher in males than in
females (15.6 vs 9.3 per 1,000 PY in all age groups; 120.6 vs 36.4 per 1,000 PY in people aged
85 years). It was lowest in those aged 35–44 years (4.5 per 1,000 PY), increased sharply with
age, and became highest in the population aged85 years (79.3 per 1,000 PY; 95%CI, 65.7 to
95.5; Fig 1). This age-associated increase in the rate was more apparent in males than in fe-
males (the point estimates of the rate ratios comparing males and females in people aged 55–64
years, 65–74 years, 75–84 years, and 85 years were 1.6, 2, 2.4, and 3.2, respectively). This in-
creasing trend was also observed for pneumonia-related hospitalizations and in-hospital death.
For the etiology-specific incidence estimates, the etiology-associated incidence rate was cal-
culated according to age group (Table 3). Although aspiration-associated pneumonia had the
highest incidence, there were substantial numbers of infection-associated pneumonia cases
among older people; S. pneumoniae-,H. influenzae-, and RV-associated pneumonia followed.
The exception was atypical pneumonia; the incidence of atypical bacteria-associated pneumo-
nia was highest among younger people (aged 15–54 years). In our study population, only 7 out
of 1,039 cases had positive blood cultures, indicating that the incidence of bacteremic pneumo-
coccal pneumonia was 12 per 100,000 PY (95% CI, 9.8 to 14.5 per 100,000 PY).
Fig 1. Annual incidences of community-onset pneumonia per 1,000 people by age group and gender. The incidence among the male population is
shown as a solid line, and the incidence among the female population is shown as a dashed line. The 95% confidence intervals for each point are shown as
vertical lines.
doi:10.1371/journal.pone.0122247.g001
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Assuming that these proportions of pneumonia etiologies were constant across all prefec-
tures, the estimated annual number of COP in the entire Japanese adult population was
1,880,000; of these, 1,300,000 cases (70%) occurred in people aged65 years (Fig 2). Seventy
percent were hospitalized cases, and 70% of all pneumonia cases were CAP. Among COP
cases, 74,000 died in hospitals. 630,000 cases were aspiration-associated, and 90% of patients
with this condition were aged65 years. 530,000 cases were S. pneumoniae-associated,
420,000 were H. influenzae-associated, and 420,000 were RV-associated pneumonia.
Discussion
To our knowledge, this study is the first to estimate the burden of pneumonia in the entire Jap-
anese adult population. In 2012, the overall incidence of community-onset pneumonia, includ-
ing CAP and HCAP, among people aged15 years was 16.9 per 1,000 PY; the incidence
sharply increased with age and reached up to 79.3 per 1,000 PY among people aged>85 years.
The estimated annual number of adult COP patients in Japan was 1,880,000, 70% of which
were elderly people aged65 years. Aspiration was the leading etiologic category of
Fig 2. Estimated annual burden of community-onset pneumonia in Japanese adults by clinical and etiological category, 2012.CAP = community-
acquired pneumonia; CI = confidence interval; HCAP = health care-associated pneumonia; HI = H. influenzae; PDR = potentially drug-resistant;
RV = respiratory virus; SP = S. pneumoniae. Maximum estimates are shown for SP- and HI-associated pneumonia.
doi:10.1371/journal.pone.0122247.g002
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pneumonia, though a substantial number of cases were still associated with infections, such as
S. pneumoniae. Our findings clearly indicate that pneumonia is an age-related disease that
causes an enormous burden in this aging population.
The burden of COP in the elderly
The incidence of pneumonia in Japanese elderly people was higher than the incidences ob-
served in large-scale population-based studies in both the United States and European coun-
tries. In Japan, the incidence of COP among people aged65 years was 42.3 per 1,000 PY; in
contrast, COP incidences were 28.4 per 1,000 PY in the United States [25], 14 per 1,000 PY in
Spain [26], and 8 per 1,000 PY in the United Kingdom [27]. The high pneumonia incidence in
Japan may be partially explained by its high proportion of extremely elderly people aged85
years (14% of the elderly population in 2012 [7]). However, the trend did not fundamentally
change after the incidence was standardized using the WHO world standard population: the
ASRs of COP among the elderly in Japan, the United States, Spain, and the United Kingdom
were 37.1, 25.3, 13.5, and 7.2 per 1,000 PY, respectively. The in-hospital mortality rate for COP
in Japan (11.5%) was lower than that reported for other countries (12.4% in the United States
[25], 15% in Spain [26], and>25% in the United Kingdom [28]). These findings suggest that
patients with mild pneumonia cases that may be overlooked in other countries are visiting clin-
ics and being diagnosed in Japan. In fact, 75% of our pneumonia cases were examined with CT
scans to diagnose pneumonia. The good access to healthcare facilities resulting from universal
health coverage and the wide use of sensitive diagnostic tools may explain this high incidence.
However, it does not indicate that the hospitalized cases in Japan are milder than those in other
countries; the proportion of severe cases (CURB65 score3) in the current study was 30%,
compared with 38% in the United Kingdom [29] and 10% in Spain [30].
The pneumonia incidence and in-hospital morality were higher among males than among
females, especially among the older age group, confirming previous works [4, 25, 26]. Consid-
ering the higher incidence of childhood pneumonia among males, they may be genetically vul-
nerable to pneumonia; however, there is no evidence to support this hypothesis.
Etiologic fractions and pneumonia control
According to our estimates, aspiration was the leading cause of pneumonia, and the burden of
pneumonia associated with aspiration was higher than that associated with any single patho-
gen, including S. pneumoniae. The burden was particularly high among the elderly population;
85.8% of aspiration-associated pneumonia cases occurred in patients aged65 years. The in-
hospital mortality for aspiration-associated pneumonia (10.9%) was higher than that for other
pneumonia categories (6%).
Aspiration-associated pneumonia has been overlooked in current pneumonia control pro-
grams. Although previous studies have shown that this condition is common among hospital-
ized pneumonia patients [2, 31], its burden has never been evaluated at the population level in
the past. Aspiration-associated pneumonia is a multi-factorial condition observed in older peo-
ple. Impaired swallowing and an abnormal cough reflex increase the risk of oropharyngeal as-
piration; the aspiration of colonized pathogens and gastric acid causes lower respiratory tract
infection and/or lung injury [12]. Compromised immunity, comorbidity and changes in lung
function in this age group underlie this condition and are associated with the high mortality.
Nursing home residents are at high risk for aspiration, but HCAP and aspiration-associated
pneumonia are not identical conditions. In fact, in our study, 25.4% of CAP and 64.3% of
HCAP cases were associated with aspiration.
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Effective clinical management and preventive measures targeting aspiration-associated
pneumonia remain underdeveloped. ATS guidelines recommend using β-lactam/β-lactamase
inhibitors for this condition [1, 13], but the management of recurrent and refractory cases is
challenging. For prevention, oral hygiene care and dysphagia rehabilitation have been sug-
gested for reducing the risk of aspiration pneumonia, but with limited supporting evidence
[32]. The burden of aspiration-associated pneumonia may further increase as the number of el-
derly people who require long-term care increases. Effective clinical and public health interven-
tion measures are urgently needed.
In the current study, S. pneumoniae was the leading single etiological pathogen and was as-
sociated with 20–28% of pneumonia, confirming previous reports [4]. Recent studies in Japan
have shown that the positivity of S. pneumoniae among CAP cases was 17% [33] to 24% [34].
According to a recent meta-analysis, the proportion of pneumococcal pneumonia among CAP
cases was 26–28% [9]. The proportion of pneumococcal pneumonia among all pneumonia
cases is declining in high-income countries, reflecting the wide use of antibiotics and pneumo-
coccal vaccines [11]. In our study, the positivity of S. pneumoniae by sputum culture was only
9%. Considering the low sensitivity of sputum culture, we included urinary antigen test-posi-
tive cases for the standard estimation and further included PCR-positive cases for the maxi-
mum estimation. The true value must lie between these values (i.e., 20 to 28%). The proportion
of bacteremia among pneumococcal pneumonia cases was 6% in our study. A meta-analysis
showed that approximately 25% of pneumococcal pneumonia is bacteremic [9]; our figure was
lower than this estimate. However, our results showed that the incidence of bacteremic pneu-
mococcal pneumonia among Japanese adults was 12 per 100,000 PY, a figure that was compa-
rable with those reported for other countries, such as the United States [35] and Australia [36].
The findings suggest that pneumococcal pneumonia, either bacteremic or non-bacteremic, re-
mains the leading target for pneumonia control programs in Japan.
PPV23 reduces the risk of invasive pneumococcal diseases (IPDs) among adults; however,
its effectiveness against pneumococcal pneumonia is still controversial, particularly for the el-
derly [37]. The recently approved PCV13 is expected to prevent almost half of the pneumococ-
cal pneumonia cases in the elderly [38, 39]; however, the vaccine covers only 13 serotypes of
pneumococcus, and its long-term effects remain unknown. In Japan, before the introduction of
PCV7 for children in 2010, 85% of IPD isolates were PPV23 serotypes, and 62% were PCV13
serotypes [40]. In the current study, 67% of the isolates were PPV23 serotypes, and 54% were
PCV13 serotypes. The vaccination policy for pneumococcus has been dramatically changing in
Japan. PCV7 for children was replaced by PCV13 in late 2013, and PPV23 was also included in
the Ministry of Health, Labour and Welfare recommended vaccines for elderly people in late
2014. The proportion of vaccine-covered serotypes is known to decline after widespread use of
PCV [41]; thus, these figures will decrease in coming years. The true efficacy of PCV13 for
adult pneumonia among the Japanese population must be evaluated along with cost-effective-
ness analyses before it is introduced into the national immunization program.
A substantial proportion of pneumonia was associated with RVs (23% of all pneumonia
cases). Recent studies suggest that RVs play crucial roles in the development of pneumonia, in-
cluding severe cases [10, 22, 42–44]; however, their biological mechanisms remain largely un-
known. RVs such as influenza, RSV, and human metapneumovirus (HMPV) cause outbreaks
among the elderly in nursing homes [45, 46], and these RVs are potential targets for vaccina-
tion. Currently, only seasonal influenza vaccines are available for adults, but their effects on
pneumonia prevention have not yet been established [47]. Further investigations are needed to
clarify the public health impact of RV-associated pneumonia in aging societies.
Our findings have important implications for effective pneumonia control programs in the
aging society. The burden of pneumonia is higher in older people, and the pneumonia etiology
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largely varies by age group: the incidences of aspiration-, S. pneumoniae-,H. influenzae-, RV-,
and PDR pathogen-associated pneumonia increase with age, while the incidence of atypical
bacteria-associated pneumonia decreases. It must be noted that the proportion of pneumonia
caused by unknown pathogens is higher among elderly people. This category most likely
represents multifactorial conditions. Therefore, in coming decades, the pneumonia burden will
likely increase, and its etiology will become more diverse. In this situation, the current etiology-
specific approach (i.e., vaccinations for pneumococcus and influenza, guidelines for appropri-
ate antibiotics use) must have only a limited impact. A multidimensional approach integrating
vaccination programs, clinical management guidelines, training for health care workers, and
education for people must be needed; further studies are warranted.
Estimation of the pneumonia burden
This study is the first to estimate the national burden of COP in Japan. Although pneumonia is
a common disease, its true burden remains unclear, even in high-income countries. A number
of studies have reported the incidence of adult pneumonia, but their estimates substantially
varied from setting to setting [4, 22, 25–28, 30, 48, 49]. Several factors explain this variation.
First, the definition of pneumonia differs among studies. Some studies have reported inci-
dences of CAP that include outpatients and hospitalized patients [25, 30, 49], while other stud-
ies have reported hospitalized cases only [28, 48]. It was not clear whether these studies
included HCAP cases. Additionally, the diagnosis of pneumonia is not standardized in clinical
settings; thus, the burden estimates based on existing database are unreliable. Second, study de-
signs vary. Pneumonia is a common disease, and it is not included in national surveillance. Co-
hort studies may not represent the entire population of a country, while hospital-based studies
do not capture all the cases in the community. Different designs may produce different esti-
mates in an identical population. Third, the health care-seeking pattern affects the incidence
estimates. Mild cases must be overlooked in countries in which access to health care is limited.
In the current study, we enrolled pneumonia cases prospectively, and all were confirmed by
study clinicians using the standardized case definition. Considering the high reliability of na-
tional statistics in Japan, our estimates can be reasonably assumed to reflect the true pneumo-
nia burden among Japanese adults.
Limitations
Our study has limitations. For the incidence estimation, we assumed that the pneumonia-out-
patient ratios in the study hospitals were constant across all hospitals in the four prefectures.
Additionally, to calculate the national burden, we assumed that the incidence of COP in the
four prefectures was constant across all prefectures. Our hospitals were community-based gen-
eral hospitals that provided primary, secondary, and tertiary care for residents; thus, the pa-
tients visiting these hospitals reflected the general population. In fact, the ASRs in the four
prefectures were almost identical in our study. Furthermore, according to the national patient
survey, the proportion of reported acute respiratory infections among all outpatients in the
four prefectures was identical to the national average (see supplementary material). We believe
that these assumptions are reasonable. In contrast, we did not consider seasonal differences in
the pneumonia etiology. Our etiology-specific burden estimates must be confirmed using
multi-year surveillance data. In this study, aspiration-associated pneumonia was defined based
on the presence of known risk factors; thus, we could not distinguish between “aspiration
pneumonia” caused by aspiration of colonized oropharyngeal pathogen or “aspiration pneu-
monitis” caused by aspiration of gastric contents [12]. However, there is no reliable marker to
identify aspiration [2]. Further studies are needed to better define this pneumonia category.
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Conclusion
A substantial portion of the COP burden in the Japanese adult population occurs in the elderly.
Aspiration was the leading etiology of pneumonia, followed by S. pneumoniae. In addition to
the introduction of vaccines for S. pneumoniae and influenza, multidimensional approaches
are urgently needed to reduce the pneumonia burden in this aging society.
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